NKTX - These Analysts Revise Their Forecasts On Nkarta After Q4 Results | Benzinga
Nkarta, Inc. (NASDAQ: NKTX) posted a loss for the fourth quarter on Thursday.
The company posted a quarterly loss of 57 cents per share, compared to market expectations for a loss of 59 cents per share, according to data from Benzinga Pro.
"Patients with severe autoimmune diseases deserve novel, effective treatments,” noted Paul J. Hastings, President and CEO of Nkarta. "Recent academic studies have shown that CD19-directed cell therapy has the promise to be truly transformative, and we believe that NKX019 may replicate these early results with superior safety and accessibility. Our approach leverages the potential advantages of NK ...